Indeed, these results suggest that pharmacologic activation of NF-κB might be a viable therapeutic option to improve cognitive function in various forms of dementia, such as Alzheimer's disease, or following traumatic or ischemic brain injury. The gene discussed is NFKB1; the disease is early-onset autosomal dominant Alzheimer disease.